0710 GMT - In Novartis's deal to buy Myricx Bio, the upfront payment relative to the potential milestones seems high, Vontobel analysts say in a note. Novartis will pay $1.1 billion upfront, with up to $400 million in potential additional payments, it said. The purchase is extraordinary to see, as Myricx Bio's platform technology hasn't reached late-stage clinical development, the Vontobel analysts say. However, it is difficult to judge with the information at hand, they add. The acquisition will bolster the Swiss pharma company's oncology offering, they say. (aimee.look@wsj.com)

(END) Dow Jones Newswires

July 06, 2026 03:10 ET (07:10 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.